Name: INOPTEC Ltd.Sector: High-Tech Hardware & Software / Wearable TechStage: Prototype ready / Seed phase still open / series AEmployees: 4 Managers, 4 R&D Members = 8 in total Founded: March 2015 = kick-off with startup activities

Contact: Ralf G.J. KnollE-Mail: ralf.knoll@inoptec.comWebsite: https://inoptec.comPhone: DE: +49 179 / 62 16 781Address: Jahnstr. 18, 85406 Zolling Germany

INOPTEC (innovation, optics, technology) is a lean, fabless, decentralised EU Start-up, registered in the UK and Germany & Ireland – run by experienced managers and engineers (opposed to Uni spin-offs), as a result of in-depth R&D over decades by its founder. | Offering a ‘licensable technology platform’ (B2B) –and WT ‘electronic eyewear’ (B2C) – both in the field of human vision enhancement. | To ensure the stability of the company (striving for zero-risk investment goals), ‘modern company growth methods’ have been employed (e.g. low fixed cost), held by modern encrypted cloud IT (DAO) & production technologies.

Ralf G.J. Knoll (1963), MSc. appl physics & EE, MSc. photonics (UK), a seasoned independent management consultant and technology expert of 20 years. Background in electronics, physics, optoelectronics, economics, coaching. Inventor, original founder, CEO / CTO.

Wilhelm Scholze (1963), Dipl.-Kfm., University of Augsburg, CEFA, CIIA Institutional Equity Sales and Vice President at Reuschel & Co. and Merck Finck & Co.He is also an investor/co-founder – and a marketing and sales expert, CSO (sports).

Dr. Pierre A. Morgon (1963), international MBA executive in med-tech (US, UK, FR, CH, DE, JP, MY) with a background in business law and pharmaceuticals. Pierre’s focus is on therapeutic and rehabilitative applications, CSO (health tech).

Company Profile

Company Summary

Management Team to name a few, more information under: http://inoptec.com/about-us/

Andreas Umbach (1961), Dipl.-Phys. TU Berlin, Formerly with Fraunhofer Heinrich-Herz-Institut, founder and CEO of U2t Photonics, which he sold to Finisar USA, served as CTO/VP of Finisar Germany. With INOPTEC, his focus is on high tech R&D, deputy CTO and COO.

Non-public/confidential 3 pager for EU compliant investors:

INOPTEC’s transhuman Vision Enhancement System (VES) enables perfect vision – day or night – under otherwise (for humans) impossible viewing conditions.The system combines ‘rapid adaptation in real time’ (human iris reflex is too slow) AND ‘contrast enhancement’ (humans cannot see against the sun).

These “new human abilities” provide a huge safety & performance advantagefor those who must safely operate vehicles, airplanes, machines, tools, computers etc. – hence reducing the risk of mistakes, accidents and injury.

Electronic eyewear AGS®Wearable Tech / AR / MR

R&D Partners with existing expertise – who have designed eyewear tech already:Award winning fashion designers, Kinneir Dufort, and PA Consulting for electronics design.R&D bootstrap team: Dr.-Ing. Joerg Gross, Wolfgang Gaerber, Martin Bayer, ... many more.

Product Services

URGENT NEED in post-modern societies: increased SAFETY & PROTETION plus better PERFORMANCE.In fast paced environments, lighting conditions are often changing faster than our eyes can adapt, causing dangerous situations. | Moreover, unwanted light (sun set, car headlights) deteriorates essential vision.

Medical • Light sensitive people & migraine patients: too much light can trigger a migraine attack. • INOPTEC’s technology variably dims the light to maintain a constant level of intensity on

the eye, e.g. 400 lux constant and always below the trigger levels of an attack (> 500 lux).• 70 million people; whilst 30 million are under treatment since they suffer a lot (SAM).

3% market share of SAM, at a sales price of 400 Euro = 360 Million Euro Revenue.

• Cyclists (racing, MTB etc.) and skiers/snowboarders – both experience rapidly changing levels of light under bright sun, e.g. when suddenly entering dark areas (tunnels/forests).

• INOPTEC is reducing the ‘dark adaption time’ from ~ 30 sec down to ZERO = instant vision.• 150 million combined cyclists and skiers; whilst 60 million are ambitiously active (SAM).

4% market share of SAM, at a sales price of 300 Euro = 720 Million Euro Revenue.

B2C end-user via own online shop and third party online shops (Kickstarter, Amazon etc.) for at least 2 years – later also OEM B2B licensing to companies like e.g. NIKE, SHIMANO, VALEO, ZEISS, HELLA-BOSCH

World’s first transhuman Vision Enhancement System (VES) enables perfect vision – day or night – under otherwise impossible viewing conditions. | No competitors, ‘first mover advantage’ ensured via 8 patentsin 10 countries (positive EPO prelim PCT research). | Strong partnerships have been established with renown WT R&D labs, producers, suppliers etc., who have successfully built pioneering WT before, so that safe routes (in time/budget/quality) can be ensured. | High demand for reliable industrial/mil grade WT.

INOPTEC’s mission is to help – via delivering urgently needed vision enhancement systems (VES) for everyone who travels fast. | No gadgets, no gimmicks – this ensures that this WT will become a necessity, like pacemakers, hearing aids, etc.Hence SAFETY, PROTECTION and PERFORMANCE will be provided to end-users.Electronic eyewear (WT) in ‘future fashion design’ – later also in conjunction withsync lighting (LED headlights or AR/HUD) – will be sold to various industries.It gives the wearer full control/power over constantly dark-adapted eyes, ready to enter dark areas <AND> to improve the ratio of wanted/unwanted light (contrast).

Starting B2C via INOPTEC’s own online shop – 1st in English speaking countries: USA, parts of EU and Asia.Secondly via online sales channels such as Kickstarter, Amazon, Alibaba, eBay. | Thirdly via retail storesand channels, such as JD, Dick’s, Decathlon, Intersport. | B2B sales via licensing to WT-eyewear brands.

None! However, some other startups (Skugga and CTRL) are trying, but they cannot: 1) dynamically adapt stepless in real-time etc. | 2) ensure dark adaption via light-tight design which is important for migraine patients and performance | 3) increase the contrast of viewing. | INOPTEC holds all important patents.

Competitive Advantage

Customer Problem / Demand within Society (#SDG)

Target Market > 1bn (go-to-market strategy: 1. migraine / 2. sports – later automotive, aviation, etc.)

Business Model / B2C and B2B

Sales / Marketing Strategy / B2C and B2B

Competitors (None, due to firm patent family – only indirect competitors and attempts)

Sports

10% of all fatal traffic accidents: due to ‘bad vision’!INOPTEC’s mission is to help! – E.g. to save lives, in line with UN SDG Health Goal 3.6 to reduce death.

Annual Financials (past and projections – with EBIT margin of ~ 40 to 50%)

Funding stage Seed / ready for series A

Capital Raised (seed) 850 k + 200 k seed open / no lock-up period, 20% LP

Capital Seeking (series A) 2.0 m (alternatively e.g. 4 x 500k)

Pre-Money valuation 5.0 m ca. only for Biz-Angel | > 10 m for series A

Run Rate (annually defined) -72 k/a in ‘idle mode’ | 20 m/a in ‘revenue mode’

Burn Rate (monthly defined) + 6 k/m in ‘idle mode’ | 0 k/m in ‘revenue mode’

2.0 Mio. Investment will be used as follows:• 800k EUR (final engineering): shrinking the circuit PCB / fashionable design / CE TUV marking

• 800k EUR (marketing & sales): online marketing (USA, EU, Asia) / production / logistics & sales

• 400k EUR (safety reserve): market ready in just 9 - 12 month / no issues with potential delays.

Go-to-market 1st year’s revenue: Please request from us the ‘ramp-up plan Excel sheet’ with careful, yet exciting, calculations and simulations.1) INOPTEC prefers to grow organically – that is why only 2.0 Mio EUR as series A investment is sought – instead of e.g. 20 Mio. EUR.2) The word wide sales numbers for a unique product, which has no competition AND is urgently needed, were estimated in a very conservativeway – prior efficient marketing campaigns: just 25k pieces sold in USA / 15k in EU / 10k in Asia / = 50k pieces x 400 EUR = 20 Mio. revenue.

7 – 10 years forecast: > 200 Mio. revenue | > 90 Mio. EBIT | EBIT margin ~ 40 to 50%

ROI Multiples expected: ROI factor > 10 in ca. 7-10 years (or earlier, no lock-up period in KCG) = IRR > 40%Similar exit cases (AR): INTEL acquired Recon for $ 175m | and 30% of Vuzix shares for $ 200m.

OFFER to INVESTORS / Return on Investment via “Exit”

Present Position / Traction / Awards & Honours

Est. 2019: INOPTEC Group Ireland Limited. Another important Holding in Dublin, IRL.

Financial Concept

Use of funds / (No R&D, just plain engineering with qualified partners who have already build similar devices)

Most important patents have been filed / Feasibility tests all successful / Test clients expressed demand

The president of AA endorsed INOPTEC publicly in THE TIMES.

Innovator of the year 2019 - AwardNo1. pitch winner: S3 San Francisco – and invited to expert pitch-events (TechTour Europe, EPIC)Top 10 innovator: nominated/selected to publicly present: on national level (BAND, LdI, IDL-social, DDW)Top 100 innovator: selected by innovateUK for #innovate2016, at New Scientist Live (#NSLive) Show.

Renown Owners (Shareholder list reads like the “CEO who’s who” of optics, photonics, suppliers)

The 100% shareholder of INOPTECis the holding KNOLL Capital Group, KCG,in which experienced partners are pooled.KCG owners and shareholders see pie chart:

7.5 % iteratec ~ BMW Mini AR glass

17.4 % top CEOs and advisors75.1 % founder, R. Knoll